ANIK Anika Therapeutics Inc.

Anika to Issue Third Quarter 2023 Financial Results on Thursday, November 2, 2023

Anika to Issue Third Quarter 2023 Financial Results on Thursday, November 2, 2023

BEDFORD, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its third quarter 2023 financial results after the close of the market on Thursday, November 2, 2023 and hold its investor conference call on the same day, at 5:30 p.m. ET to discuss its financial results and business highlights.

The conference call can be accessed by dialing 1-844-826-3035 (toll-free domestic) or 1-412-317-5195 (international) and providing the conference ID number 10182980. A live audio webcast will be available in the section of Anika's website, . An accompanying slide presentation also can be accessed via the Anika website. The call will be archived and accessible on the same website shortly after its conclusion.

About Anika

(NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit

ANIKA, ANIKA THERAPEUTICS and the Anika logo are registered trademarks of Anika Therapeutics, Inc.

For Investor Inquiries:

Anika Therapeutics, Inc.

Mark Namaroff, 781-457-9287

Vice President, Investor Relations, ESG and Corporate Communications



EN
10/10/2023

Underlying

ANIKAnika Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Anika Therapeutics Inc.

 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on May 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 5,000 shares of common stock at a per share exercise price of $14.46, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to two newly hir...

May 12, 2025 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika Reports First Quarter 2025 Financial Results

Anika Reports First Quarter 2025 Financial Results First Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating Fiscal 2025 OEM Channel revenue guidance and Adjusted EBITDA guidance BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early interventio...

May 9, 2025 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika to Participate in the Sidoti Virtual Investor Conference

Anika to Participate in the Sidoti Virtual Investor Conference BEDFORD, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that management will participate in the Sidoti Virtual Investor Conference on Wednesday, May 21, 2025. Anika will host a virtual presentation with Q&A starting at 1:00pm ET. Webcast of the presentation and Q&A will be available in the  section of Anika’s website, . An archive of the presentation will also be a...

May 7, 2025 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, ...

Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025 BEDFORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2025 financial results before the opening of the market on Friday, May 9, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID numb...

April 25, 2025 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global leader in the Osteoarthritis (“OA”) Pain Management and Regenerative Solutions space focused on early intervention orthopedics, today announced that on April 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 3,800 shares of common stock at a per share exercise price of $15.03, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly ...

April 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch